{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:38:34Z","timestamp":1778474314840,"version":"3.51.4"},"reference-count":222,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccination is arguably the most cost-effective preventative measure against infectious diseases. While vaccines have been successfully developed against certain viruses (e.g., yellow fever virus, polio virus, and human papilloma virus HPV), those against a number of other important public health threats, such as HIV-1, hepatitis C, and respiratory syncytial virus (RSV), have so far had very limited success. The global pandemic of COVID-19, caused by the SARS-CoV-2 virus, highlights the urgency of vaccine development against this and other constant threats of zoonotic infection. While some traditional methods of producing vaccines have proven to be successful, new concepts have emerged in recent years to produce more cost-effective and less time-consuming vaccines that rely on viral vectors to deliver the desired immunogens. This review discusses the advantages and disadvantages of different viral vaccine vectors and their general strategies and applications in both human and veterinary medicines. A careful review of these issues is necessary as they can provide important insights into how some of these viral vaccine vectors can induce robust and long-lasting immune responses in order to provide protective efficacy against a variety of infectious disease threats to humans and animals, including those with zoonotic potential to cause global pandemics.<\/jats:p>","DOI":"10.3390\/vaccines8040680","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T08:44:02Z","timestamp":1605257042000},"page":"680","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1679-8240","authenticated-orcid":false,"given":"Sophia M.","family":"Vrba","sequence":"first","affiliation":[{"name":"Department of Veterinary &amp; Biomedical Sciences, University of Minnesota, Twin Cities, St. Paul, MN 55108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-4045","authenticated-orcid":false,"given":"Natalie M.","family":"Kirk","sequence":"additional","affiliation":[{"name":"Comparative Molecular Biosciences Graduate Program, Department of Veterinary &amp; Biomedical Sciences, University of Minnesota, Twin Cities, St. Paul, MN 55108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7040-4495","authenticated-orcid":false,"given":"Morgan E.","family":"Brisse","sequence":"additional","affiliation":[{"name":"Biochemistry, Molecular Biology and Biophysics Graduate Program, Department of Veterinary &amp; Biomedical Sciences, University of Minnesota, Twin Cities, St. Paul, MN 55108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6002-6868","authenticated-orcid":false,"given":"Yuying","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Veterinary &amp; Biomedical Sciences, University of Minnesota, Twin Cities, St. Paul, MN 55108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hinh","family":"Ly","sequence":"additional","affiliation":[{"name":"Department of Veterinary &amp; Biomedical Sciences, University of Minnesota, Twin Cities, St. Paul, MN 55108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"ref_1","unstructured":"(2020, November 13). FDA Vaccines Licensed for Use in the United States, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jmv.25593","article-title":"Why are vaccines against many human viral diseases still unavailable; an historic perspective?","volume":"92","author":"Tannock","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/302490a0","article-title":"Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen","volume":"302","author":"Smith","year":"1983","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/311067a0","article-title":"Live recombinant vaccinia virus protects chimpanzees against hepatitis B","volume":"311","author":"Moss","year":"1984","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S0950268800052535","article-title":"The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; A link between Jenner and Pasteur","volume":"116","author":"Pastoret","year":"1996","journal-title":"Epidemiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0065-3519(99)80043-3","article-title":"Van Vaccination of wildlife against rabies: Successful use of a vectored vaccine obtained by recombinant technology","volume":"41","author":"Mackowiak","year":"1999","journal-title":"Adv. Vet. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","article-title":"Lentiviral vectors in gene therapy: Their current status and future potential","volume":"58","author":"Escors","year":"2010","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_10","first-page":"163","article-title":"Single-cycle adenovirus vectors in the current vaccine landscape","volume":"17","author":"Barry","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14712598.2010.519332","article-title":"Production of adenovirus vectors and their use as a delivery system for influenza vaccines","volume":"10","author":"Vemula","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.55.091902.104344","article-title":"Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors","volume":"55","author":"Shiver","year":"2004","journal-title":"Annu. Rev. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: The first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/v7041726","article-title":"The evolution of poxvirus vaccines","volume":"7","author":"Perdiguero","year":"2015","journal-title":"Viruses"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development","volume":"Volume 97","author":"Volz","year":"2017","journal-title":"Advances in Virus Research"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0264-410X(88)90100-4","article-title":"Recombinant fowlpox virus inducing protective immunity in non-avian species","volume":"6","author":"Taylor","year":"1988","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.vaccine.2017.12.046","article-title":"Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins","volume":"36","author":"Wang","year":"2018","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nbt1291-1356","article-title":"A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon","volume":"9","author":"Garoff","year":"1991","journal-title":"Nat. Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.0900088106","article-title":"Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest","volume":"106","author":"Emonet","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.virol.2011.01.013","article-title":"Arenavirus reverse genetics: New approaches for the investigation of arenavirus biology and development of antiviral strategies","volume":"411","author":"Emonet","year":"2011","journal-title":"Virology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4939-6869-5_10","article-title":"Recombinant Tri-Segmented Pichinde Virus as a Novel Live Viral Vaccine Platform","volume":"1581","author":"Dhanwani","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1172\/JCI43961","article-title":"Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties","volume":"120","author":"Slavuljica","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3389\/fimmu.2018.00991","article-title":"Murine CMV Expressing the High Affinity NKG2D Ligand MULT-1: A Model for the Development of Cytomegalovirus-Based Vaccines","volume":"9","author":"Reichel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00298-16","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and Multipathogen Viral Vector Vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev. Med. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/14760584.2018.1406800","article-title":"The 17D-204 and 17DD yellow fever vaccines: An overview of major similarities and subtle differences","volume":"17","author":"Muniz","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/icb.2010.155","article-title":"Insights into human CD8+ T-cell memory using the yellow fever and smallpox vaccines","volume":"89","author":"Ahmed","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vaccine.2010.10.024","article-title":"Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response","volume":"29","author":"DiNapoli","year":"2010","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/j.vaccine.2014.04.068","article-title":"A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens","volume":"32","author":"Basavarajappa","year":"2014","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1073\/pnas.95.7.3501","article-title":"Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus","volume":"95","author":"Wertz","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1128\/JVI.73.6.4705-4712.1999","article-title":"Phenotypic Consequences of Rearranging the P, M, and G Genes of Vesicular Stomatitis Virus","volume":"73","author":"Ball","year":"1999","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gomme, E.A., Faul, E.J., Flomenberg, P., McGettigan, J.P., and Schnell, M.J. (2010). Characterization of a Single-Cycle Rabies Virus-Based Vaccine Vector. J. Virol.","DOI":"10.1128\/JVI.01870-09"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1099\/0022-1317-81-9-2147","article-title":"Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: An in vitro and in vivo study","volume":"81","author":"Etessami","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.virol.2009.08.038","article-title":"Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents","volume":"394","author":"Shashkova","year":"2009","journal-title":"Virology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e13527","DOI":"10.1111\/ctr.13527","article-title":"Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Florescu","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10200","DOI":"10.1128\/JVI.79.16.10200-10209.2005","article-title":"Replicating Rather than Nonreplicating Adenovirus-Human Immunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity and Priming High-Titer Antibodies","volume":"79","author":"Peng","year":"2005","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e01648-18","DOI":"10.1128\/JVI.01648-18","article-title":"Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses","volume":"93","author":"Chea","year":"2019","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.virol.2005.09.020","article-title":"Replication-defective viruses as vaccines and vaccine vectors","volume":"344","author":"Dudek","year":"2006","journal-title":"Virology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_42","unstructured":"(2020, September 01). First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response | FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health."},{"key":"ref_43","unstructured":"(2020, November 10). ERVEBO\u00ae [Ebola Zaire Vaccine (rVSV\u0394G-ZEBOV-GP) live] Awarded Prequalification Status by the World Health Organization (WHO)\u2014Merck.com. Available online: https:\/\/www.merck.com\/news\/ervebo-ebola-zaire-vaccine-rvsv\u03b4g-zebov-gp-live-awarded-prequalification-status-by-the-world-health-organization-who\/."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/21645515.2018.1513439","article-title":"Poxviral promoters for improving the immunogenicity of MVA delivered vaccines","volume":"15","author":"Alharbi","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1128\/JVI.02184-14","article-title":"Amplified and Persistent Immune Responses Generated by Single-Cycle Replicating Adenovirus Vaccines","volume":"89","author":"Crosby","year":"2015","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/hgtb.2017.084","article-title":"Pseudotyped Lentiviral Vectors: One Vector, Many Guises","volume":"28","author":"Joglekar","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-virology-100114-055043","article-title":"Retroviral Integrase: Then and Now","volume":"2","author":"Andrake","year":"2015","journal-title":"Annu. Rev. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/gt.2010.135","article-title":"Development of murine leukemia virus-based retroviral vectors with a minimum possibility of cis-activation","volume":"18","author":"Jang","year":"2011","journal-title":"Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2249.2000.01359.x","article-title":"Severe combined immunodeficiencies (SCID)","volume":"122","author":"Fischer","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/nm1297-1354","article-title":"Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells","volume":"3","author":"Ram","year":"1997","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/mthe.2000.0027","article-title":"Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system","volume":"1","author":"Schroers","year":"2000","journal-title":"Mol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/85664","article-title":"Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo","volume":"19","author":"Kobinger","year":"2001","journal-title":"Nat. Biotechnol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1006\/mthe.2002.0584","article-title":"Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins","volume":"5","author":"Watson","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1182\/blood-2008-05-155945","article-title":"Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins","volume":"112","author":"Frecha","year":"2008","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.virol.2014.05.030","article-title":"IIIa deleted adenovirus as a single-cycle genome replicating vector","volume":"462\u2013463","author":"Crosby","year":"2014","journal-title":"Virology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/infdis\/jiy411","article-title":"A replicating single-cycle adenovirus vaccine against Ebola virus","volume":"218","author":"Matchett","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00720-16","DOI":"10.1128\/JVI.00720-16","article-title":"Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses","volume":"91","author":"Crosby","year":"2017","journal-title":"J. Virol."},{"key":"ref_58","first-page":"161","article-title":"Poxviruses as vectors for cancer immunotherapy","volume":"6","author":"Kwak","year":"2003","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0264-410X(91)90152-V","article-title":"Efficacy studies on a canarypox-rabies recombinant virus","volume":"9","author":"Taylor","year":"1991","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1128\/JVI.02386-13","article-title":"The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys","volume":"88","author":"Teigler","year":"2014","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1172\/JCI9819","article-title":"Poxvirus vectors: Orphaned and underappreciated","volume":"105","author":"Mastrangelo","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"16003","DOI":"10.1038\/npjvaccines.2016.3","article-title":"Protection from Hendra virus infection with Canarypox recombinant vaccine","volume":"1","author":"Lemaitre","year":"2016","journal-title":"npj Vaccines"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/hv.20778","article-title":"Poxvirus vectors as HIV\/AIDS vaccines in humans","volume":"8","author":"Perdiguero","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Pitisuttithum","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.aids.0000199819.40079.e9","article-title":"A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1","volume":"20","author":"Kelleher","year":"2006","journal-title":"AIDS"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.vaccine.2004.05.024","article-title":"Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN\u03b3 or IL-12","volume":"23","author":"Dale","year":"2004","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/JVI.01727-06","article-title":"Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques","volume":"81","author":"Batten","year":"2007","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.vaccine.2004.10.012","article-title":"Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: Safety and T cell immunogenicity in macaques","volume":"23","author":"Chea","year":"2005","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1128\/JVI.02000-10","article-title":"Antigen-specific T-cell responses to a recombinant fowlpox virus are dependent on MyD88 and interleukin-18 and independent of Toll-like receptor 7 (TLR7)- and TLR9-mediated innate immune recognition","volume":"85","author":"Lousberg","year":"2011","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/rmv.360","article-title":"Alphavirus vectors and vaccination","volume":"12","author":"Rayner","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14712598.1.2.177","article-title":"Alphavirus vectors: Development and potential therapeutic applications","volume":"1","author":"Schlesinger","year":"2001","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1126\/science.2922607","article-title":"Sindbis virus: An efficient, broad host range vector for gene expression in animal cells","volume":"243","author":"Xiong","year":"1989","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0042-6822(89)90526-6","article-title":"In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant","volume":"171","author":"Davis","year":"1989","journal-title":"Virology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/jvi.71.4.2819-2829.1997","article-title":"Sindbis virus replicons and Sindbis virus: Assembly of chimeras and of particles deficient in virus RNA","volume":"71","author":"Frolov","year":"1997","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/JVI.73.2.1092-1098.1999","article-title":"Two-Helper RNA System for Production of Recombinant Semliki Forest Virus Particles","volume":"73","author":"Smerdou","year":"1999","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00262-018-2276-z","article-title":"An alphavirus-based therapeutic cancer vaccine: From design to clinical trial","volume":"68","author":"Singh","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1128\/JVI.74.2.914-922.2000","article-title":"Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis","volume":"74","author":"MacDonald","year":"2000","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.vaccine.2003.10.003","article-title":"Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: Indications for cross-priming","volume":"22","author":"Huckriede","year":"2004","journal-title":"Vaccine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1743-422X-8-36","article-title":"Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines","volume":"8","author":"Kostic","year":"2011","journal-title":"Virol. J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1089\/aid.1998.14.1369","article-title":"Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant semliki forest virus RNA, or recombinant semliki forest virus particles","volume":"14","author":"Brand","year":"1998","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/viro.1998.9357","article-title":"DNA-Based and Alphavirus-Vectored Immunisation with PrM and E Proteins Elicits Long-Lived and Protective Immunity against the Flavivirus, Murray Valley Encephalitis Virus","volume":"250","author":"Colombage","year":"1998","journal-title":"Virology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0264-410X(98)00224-2","article-title":"Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice","volume":"17","author":"Berglund","year":"1999","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1128\/JVI.72.8.6907-6910.1998","article-title":"Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice","volume":"72","author":"Tsuji","year":"1998","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/viro.1999.9961","article-title":"Comparison of the Protective Efficacy of Naked DNA, DNA-based Sindbis Replicon, and Packaged Sindbis Replicon Vectors Expressing Hantavirus Structural Genes in Hamsters","volume":"263","author":"Kamrud","year":"1999","journal-title":"Virology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/sj.gt.3302536","article-title":"Induction of human papilloma virus E6\/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6\/E7-transgenic mice","volume":"12","author":"Regts","year":"2005","journal-title":"Gene Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1006\/viro.2001.1012","article-title":"Vaccine Potential of Ebola Virus VP24, VP30, VP35, and VP40 Proteins","volume":"286","author":"Wilson","year":"2001","journal-title":"Virology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1128\/JVI.75.6.2660-2664.2001","article-title":"Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein","volume":"75","author":"Wilson","year":"2001","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/viro.1998.9367","article-title":"Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates","volume":"251","author":"Hevey","year":"1998","journal-title":"Virology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/JVI.74.1.371-378.2000","article-title":"Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles","volume":"74","author":"Davis","year":"2000","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/IAI.69.9.5709-5715.2001","article-title":"Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system","volume":"69","author":"Lee","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1073\/pnas.92.7.3009","article-title":"Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus","volume":"92","author":"Zhou","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/jvi.70.7.4761-4766.1996","article-title":"Phenotypic changes in Langerhans\u2019 cells after infection with arboviruses: A role in the immune response to epidermally acquired viral infection?","volume":"70","author":"Johnston","year":"1996","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2019). Plasmid DNA-based Alphavirus Vaccines. Vaccines, 7.","DOI":"10.3390\/vaccines7010029"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1172\/JCI42672","article-title":"An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1128\/CVI.00258-12","article-title":"Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults","volume":"19","author":"Wecker","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.057000-0","article-title":"Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections","volume":"95","author":"McLay","year":"2014","journal-title":"J. Gen. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.spen.2012.02.002","article-title":"Lymphocytic choriomeningitis virus: An underrecognized cause of neurologic disease in the fetus, child, and adult","volume":"19","author":"Bonthius","year":"2012","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa053240","article-title":"Transmission of lymphocytic choriomeningitis virus by organ transplantation","volume":"354","author":"Fischer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jmv.10389","article-title":"Lymphocytic choriomeningitis virus infection in a province of Spain: Analysis of sera from the general population and wild rodents","volume":"70","author":"Saz","year":"2003","journal-title":"J. Med. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1128\/iai.9.5.821-823.1974","article-title":"Serological evidence of infection by Pichinde virus among laboratory workers","volume":"9","author":"Buchmeier","year":"1974","journal-title":"Infect. Immun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"44875","DOI":"10.18632\/oncotarget.10405","article-title":"Arenaviral vaccine vectors to combat infectious diseases","volume":"7","author":"Dhanwani","year":"2016","journal-title":"Oncotarget"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7373","DOI":"10.1128\/JVI.00307-15","article-title":"Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines","volume":"89","author":"Cheng","year":"2015","journal-title":"J. Virol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vaccine.2016.11.063","article-title":"Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens","volume":"35","author":"Shields","year":"2017","journal-title":"Vaccine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1128\/JVI.02705-15","article-title":"A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose","volume":"90","author":"Dhanwani","year":"2015","journal-title":"J. Virol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Sommerstein, R., Flatz, L., Remy, M.M., Malinge, P., Magistrelli, G., Fischer, N., Sahin, M., Bergthaler, A., Igonet, S., and ter Meulen, J. (2015). Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLOS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005276"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00430-019-00597-7","article-title":"Del Vaccine vectors: The bright side of cytomegalovirus","volume":"208","author":"Val","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"362ra145 LP-362ra145","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nm.1935","article-title":"Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge","volume":"15","author":"Hansen","year":"2009","journal-title":"Nat. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.vaccine.2015.03.029","article-title":"A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose","volume":"33","author":"Tsuda","year":"2015","journal-title":"Vaccine"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"21674","DOI":"10.1038\/srep21674","article-title":"Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection","volume":"6","author":"Marzi","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1016\/j.vaccine.2012.02.043","article-title":"A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice","volume":"30","author":"Tierney","year":"2012","journal-title":"Vaccine"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.4049\/jimmunol.1302523","article-title":"A Novel Murine Cytomegalovirus Vaccine Vector Protects against Mycobacterium tuberculosis","volume":"193","author":"Beverley","year":"2014","journal-title":"J. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.4473","article-title":"Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine","volume":"24","author":"Hansen","year":"2018","journal-title":"Nat. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","article-title":"Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: Neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA","volume":"4","author":"Niedrig","year":"1999","journal-title":"Trop. Med. Int. Health"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8 T Cell Response","volume":"183","author":"Akondy","year":"2009","journal-title":"J. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.mi.44.100190.003245","article-title":"Flavivirus Genome Organization, Expression, and Replication","volume":"44","author":"Chambers","year":"1990","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","article-title":"Yellow fever\/Japanese encephalitis chimeric viruses: Construction and biological properties","volume":"73","author":"Chambers","year":"1999","journal-title":"J. Virol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J. Virol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/JVI.75.16.7290-7304.2001","article-title":"Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine","volume":"75","author":"Guirakhoo","year":"2001","journal-title":"J. Virol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","article-title":"Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil","volume":"89","author":"Dayan","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.vaccine.2013.08.088","article-title":"Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA","volume":"31","author":"Dayan","year":"2013","journal-title":"Vaccine"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum. Vaccin."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","article-title":"Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans","volume":"85","author":"Qiao","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0264-410X(01)00457-1","article-title":"Clinical proof of principle for ChimeriVaxTM: Recombinant live, attenuated vaccines against flavivirus infections","volume":"20","author":"Monath","year":"2002","journal-title":"Vaccine"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/INF.0b013e3181f68e9c","article-title":"Safety and immunogenicity of a single administration of live-attenuated japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: Multicenter randomized controlled trial","volume":"29","author":"Chokephaibulkit","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric Live, Attenuated Vaccine against Japanese Encephalitis (ChimeriVax-JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge with Inactivated Japanese Encephalitis Antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1297-9716-43-16","article-title":"Recent progress in West Nile virus diagnosis and vaccination","volume":"43","author":"Ulbert","year":"2012","journal-title":"Vet. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"13206","DOI":"10.1038\/s41598-018-31375-9","article-title":"Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine","volume":"8","author":"Goncalvez","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1743-422X-4-115","article-title":"Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes","volume":"4","author":"Bonaldo","year":"2007","journal-title":"Virol. J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1590\/S0074-02762012000200017","article-title":"Retention of a recombinant GFP protein expressed by the yellow fever 17D virus in the E\/NS1 intergenic region in the endoplasmic reticulum","volume":"107","author":"Trindade","year":"2012","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Martins, M.A., Bonaldo, M.C., Rudersdorf, R.A., Piaskowski, S.M., Rakasz, E.G., Weisgrau, K.L., Furlott, J.R., Eernisse, C.M., de Santana, M.G.V., and Hidalgo, B. (2013). Immunogenicity of Seven New Recombinant Yellow Fever Viruses 17D Expressing Fragments of SIVmac239 Gag, Nef, and Vif in Indian Rhesus Macaques. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054434"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e59347","DOI":"10.1371\/journal.pone.0059347","article-title":"Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi","volume":"8","author":"Nogueira","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1016\/j.vaccine.2010.06.052","article-title":"Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development","volume":"28","author":"Franco","year":"2010","journal-title":"Vaccine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs","volume":"29","author":"Jiang","year":"2011","journal-title":"Vaccine"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1128\/JVI.79.8.4599-4609.2005","article-title":"Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication","volume":"79","author":"Deas","year":"2005","journal-title":"J. Virol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.antiviral.2011.05.001","article-title":"Development and characterization of a stable luciferase dengue virus for high-throughput screening","volume":"91","author":"Zou","year":"2011","journal-title":"Antiviral Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.4161\/hv.28117","article-title":"The yellow fever 17D virus as a platform for new live attenuated vaccines","volume":"10","author":"Bonaldo","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Alexander, D.J. (2000). Newcastle disease and other avian paramyxoviruses. OIE Rev. Sci. Tech.","DOI":"10.20506\/rst.19.2.1231"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1128\/JVI.75.23.11868-11873.2001","article-title":"Recombinant Newcastle disease virus as a vaccine vector","volume":"75","author":"Nakaya","year":"2001","journal-title":"J. Virol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.vaccine.2010.01.001","article-title":"Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1016\/j.vaccine.2010.02.051","article-title":"Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1","volume":"28","author":"Khattar","year":"2010","journal-title":"Vaccine"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1016\/j.vaccine.2014.06.061","article-title":"Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e75456","DOI":"10.1371\/journal.pone.0075456","article-title":"Evaluation of the replication, pathogenicity, and immunogenicity of avian paramyxovirus (APMV) serotypes 2, 3, 4, 5, 7, and 9 in rhesus macaques","volume":"8","author":"Khattar","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Yoshida, A., Kim, S.-H., Manoharan, V.K., Varghese, B.P., Paldurai, A., and Samal, S. (2019). Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-42004-4"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fmicb.2017.00693","article-title":"Avian Paramyxovirus Type-3 as a Vaccine Vector: Identification of a Genome Location for High Level Expression of a Foreign Gene","volume":"8","author":"Yoshida","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Rose, J., and Schubert, M. (1987). Rhabdovirus Genomes and Their Products. The Rhabdoviruses, Springer.","DOI":"10.1007\/978-1-4684-7032-1_4"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1073\/pnas.97.7.3544","article-title":"Recombinant rabies virus as potential live-viral vaccines for HIV-1","volume":"97","author":"Schnell","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"P787","DOI":"10.1016\/S0140-6736(18)31710-0","article-title":"Prevention of Ebola virus disease through vaccination: Where we are in 2018","volume":"392","author":"Lane","year":"2018","journal-title":"Lancet"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(18)30559-2","article-title":"Questionable efficacy of the rVSV-ZEBOV Ebola vaccine\u2014Authors\u2019 reply","volume":"391","author":"Longini","year":"2018","journal-title":"Lancet"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Keusch, G.T., McAdam, K., Cuff, P.A., Mancher, M., and Busta, E.R. (2017). Integrating Clinical Research into Epidemic Response: The Ebola Experience, National Academies Press.","DOI":"10.17226\/24739"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Rep."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Emanuel, J., Callison, J., Dowd, K.A., Pierson, T.C., Feldmann, H., and Marzi, A. (2018). A VSV-based Zika virus vaccine protects mice from lethal challenge. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-29401-x"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12981-017-0179-2","article-title":"Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses","volume":"14","author":"Racine","year":"2017","journal-title":"AIDS Res. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Bishnoi, S., Tiwari, R., Gupta, S., Byrareddy, S.N., and Nayak, D. (2018). Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Viruses, 10.","DOI":"10.3390\/v10020090"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/cne.903560312","article-title":"Specificity of rabies virus as a transneuronal tracer of motor networks: Transfer from hypoglossal motoneurons to connected second-order and higher order central nervous system cell groups","volume":"356","author":"Ugolini","year":"1995","journal-title":"J. Comp. Neurol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jneumeth.2009.12.001","article-title":"Advances in viral transneuronal tracing","volume":"194","author":"Ugolini","year":"2010","journal-title":"J. Neurosci. Methods"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/nprot.2013.094","article-title":"Design and generation of recombinant rabies virus vectors","volume":"8","author":"Osakada","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.neuron.2007.01.033","article-title":"Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons","volume":"53","author":"Wickersham","year":"2007","journal-title":"Neuron"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1128\/JVI.77.20.10889-10899.2003","article-title":"Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome","volume":"77","author":"McGettigan","year":"2003","journal-title":"J. Virol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"11366","DOI":"10.1073\/pnas.93.21.11366","article-title":"Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein","volume":"93","author":"Mebatsion","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/JVI.77.1.237-244.2003","article-title":"Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic","volume":"77","author":"McGettigan","year":"2003","journal-title":"J. Virol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-019-0109-5","article-title":"Rabies-based vaccine induces potent immune responses against Nipah virus","volume":"4","author":"Keshwara","year":"2019","journal-title":"npj Vaccines"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nmeth999","article-title":"Retrograde neuronal tracing with a deletion-mutant rabies virus","volume":"4","author":"Wickersham","year":"2007","journal-title":"Nat. Methods"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1016\/j.vaccine.2008.09.044","article-title":"Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems","volume":"26","author":"Brun","year":"2008","journal-title":"Vaccine"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2018.02.002","article-title":"Recent advances in viral vectors in veterinary vaccinology","volume":"29","author":"Baron","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/sj.gt.3302618","article-title":"Use of adenoviral vectors as veterinary vaccines","volume":"12","author":"Ferreira","year":"2005","journal-title":"Gene Ther."},{"key":"ref_177","unstructured":"(2020, November 13). Veterinary Biological Products Licensees and Permittees, Available online: https:\/\/www.aphis.usda.gov\/animal_health\/vet_biologics\/publications\/currentprodcodebook.pdf."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jcpa.2007.04.015","article-title":"Immunization of puppies in the presence of maternally derived antibodies against canine distemper virus","volume":"137","author":"Pardo","year":"2007","journal-title":"J. Comp. Pathol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1128\/jvi.67.4.2370-2375.1993","article-title":"Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL","volume":"67","author":"Tartaglia","year":"1993","journal-title":"J. Virol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1128\/JVI.74.14.6358-6367.2000","article-title":"Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines","volume":"74","author":"Welter","year":"2000","journal-title":"J. Virol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1016\/j.vaccine.2012.09.068","article-title":"Three-year duration of immunity in cats vaccinated with a canarypox-vectored recombinant rabies virus vaccine","volume":"30","author":"Jas","year":"2012","journal-title":"Vaccine"},{"key":"ref_182","first-page":"5391","article-title":"Postvaccinal sarcomas in the cat: Epidemiology and electron probe microanalytical identification of aluminum","volume":"52","author":"Hendrick","year":"1992","journal-title":"Cancer Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/1098612X15588451","article-title":"Feline injection-site sarcoma: ABCD guidelines on prevention and management","volume":"17","author":"Hartmann","year":"2015","journal-title":"J. Feline Med. Surg."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13567-017-0459-9","article-title":"Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG\u00ae): A global review","volume":"48","author":"Maki","year":"2017","journal-title":"Vet. Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/B978-0-12-387040-7.00019-6","article-title":"Evolution of wildlife rabies control tactics","volume":"79","author":"Rosatte","year":"2011","journal-title":"Adv. Virus Res."},{"key":"ref_186","unstructured":"Greene, J.L. (2014). Update on the Highly-Pathogenic Avian Influenza Outbreak of 2014\u20132015."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2307\/1588488","article-title":"Protection against Marek\u2019s Disease by Vaccination with a Herpesvirus of Turkeys","volume":"14","author":"Okazaki","year":"1970","journal-title":"Avian Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2307\/1591544","article-title":"Protection of chickens from Newcastle and Marek\u2019s diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein","volume":"36","author":"Morgan","year":"1992","journal-title":"Avian Dis."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/03079457.2011.631983","article-title":"Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens","volume":"41","author":"Vagnozzi","year":"2012","journal-title":"Avian Pathol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1006\/viro.1995.1430","article-title":"Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens","volume":"211","author":"Darteil","year":"1995","journal-title":"Virology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jcpa.2007.04.017","article-title":"Use of a vectored vaccine against infectious bursal disease of chickens in the face of high-titred maternally derived antibody","volume":"137","author":"Bublot","year":"2007","journal-title":"J. Comp. Pathol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.vaccine.2008.10.094","article-title":"Field efficacy trial of a novel HVT-IBD vector vaccine for 1-day-old broilers","volume":"27","author":"Dancer","year":"2009","journal-title":"Vaccine"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41541-018-0056-6","article-title":"Gallid herpesvirus 3 SB-1 strain as a recombinant viral vector for poultry vaccination","volume":"3","author":"Sadigh","year":"2018","journal-title":"npj Vaccines"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.vaccine.2017.12.025","article-title":"A simple and rapid approach to develop recombinant avian herpesvirus vectored vaccines using CRISPR\/Cas9 system","volume":"36","author":"Tang","year":"2018","journal-title":"Vaccine"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Tang, N., Zhang, Y., Sadigh, Y., Moffat, K., Shen, Z., Nair, V., and Yao, Y. (2020). Generation of A Triple Insert Live Avian Herpesvirus Vectored Vaccine Using CRISPR\/Cas9-Based Gene Editing. Vaccines, 8.","DOI":"10.3390\/vaccines8010097"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging Concepts and Technologies in Vaccine Development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1016\/j.vaccine.2013.04.016","article-title":"Humoral immune response to oral rabies vaccination in raccoon kits: Problems and implications","volume":"31","author":"Fry","year":"2013","journal-title":"Vaccine"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/jvi.71.5.3677-3683.1997","article-title":"The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus","volume":"71","author":"Wang","year":"1997","journal-title":"J. Virol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1099\/0022-1317-80-5-1263","article-title":"Mucosal immunization of calves with recombinant bovine adenovirus-3: Induction of protective immunity to bovine herpesvirus-1","volume":"80","author":"Zakhartchouk","year":"1999","journal-title":"J. Gen. Virol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/S0264-410X(02)00344-4","article-title":"Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge","volume":"20","author":"Fischer","year":"2002","journal-title":"Vaccine"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.micinf.2008.04.005","article-title":"Bovine tuberculosis as a model for human tuberculosis: Advantages over small animal models","volume":"10","author":"Godfroid","year":"2008","journal-title":"Microbes Infect."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1128\/IAI.00287-09","article-title":"Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis","volume":"77","author":"Vordermeier","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Kaufmann, S.H.E. (2020). Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00316"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2019-126007","article-title":"Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia a Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration","volume":"134","author":"Nguyen","year":"2019","journal-title":"Blood"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2217\/fvl.12.65","article-title":"Use of replication-defective adenoviruses to develop vaccines and biotherapeutics against foot-and-mouth disease","volume":"7","author":"Grubman","year":"2012","journal-title":"Future Virol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J.N., Port, J.R., Avanzato, V.A., Bushmaker, T., Flaxman, A., and Ulaszewska, M. (2020). ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 1\u20138.","DOI":"10.1101\/2020.05.13.093195"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"eaba8399","DOI":"10.1126\/sciadv.aba8399","article-title":"A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques","volume":"6","author":"Haddock","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_210","unstructured":"(2020, November 10). COVID-19 Vaccine Trial Pauses After Adverse Reaction|The Scientist Magazine\u00ae. Available online: https:\/\/www.the-scientist.com\/news-opinion\/covid-19-vaccine-trial-pauses-after-adverse-reaction-67917."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"ref_213","unstructured":"(2020, November 10). Johnson & Johnson Covid-19 Vaccine Study Paused Due to Illness. Available online: https:\/\/www.statnews.com\/2020\/10\/12\/johnson-johnson-covid-19-vaccine-study-paused-due-to-unexplained-illness-in-participant\/."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"m3205","DOI":"10.1136\/bmj.m3205","article-title":"Covid-19: Russia approves vaccine without large scale testing or published results","volume":"370","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Burki, T.K. (2020). The Russian vaccine for COVID-19. Lancet Respir. Med.","DOI":"10.1016\/S2213-2600(20)30402-1"},{"key":"ref_216","unstructured":"(2020, November 10). GRAd-COV2 Vaccine Against COVID-19\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04528641."},{"key":"ref_217","unstructured":"(2020, November 10). Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04563702."},{"key":"ref_218","unstructured":"(2020, September 06). Clinical Trial to Evaluate the Safety and Immunogenicitiy of the COVID-19 Vaccine\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04497298."},{"key":"ref_219","unstructured":"(2020, September 06). A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04498247."},{"key":"ref_220","unstructured":"(2020, November 10). Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04569786."},{"key":"ref_221","unstructured":"(2020, November 10). Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04569383."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"m3096","DOI":"10.1136\/bmj.m3096","article-title":"Covid-19: Where are we on immunity and vaccines?","volume":"370","author":"Mahase","year":"2020","journal-title":"BMJ"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/680\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:33:09Z","timestamp":1760178789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":222,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040680"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040680","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]}}}